Table 6.9.

Examples of Mycobacterium tuberculosis vaccines in development

Approach	Vaccine name	Comment	Manufacturer
Early-stage development (Phase I)
TLR9 agonist, fusion protein H4	SSI HyVac4 (AERAS-404)	Adjuvanted with IC31™	Statens Serum Institut, Sanofi Pasteur, Intercell and Aeras
Mid-stage development (Phase II)
Fusion protein	GSK M72	Adjuvanted with AS01	GSK Biologicals
Adenovirus vector 35	Crucell Ad35 (AERAS-402)	Viral vector	Crucell
Modified vaccinia Ankara virus	MVA85A (AERAS-485)	Viral vector	The Oxford-Emergent TB Consortium Ltd

TLR, Toll-like receptor; SSI, Statens Serum Institut; AERAS, The Aeras Global TB Vaccine Foundation; GSK, GlaxoSmithKline; AS, Adjuvant Systems; MVA, modified vaccinia Ankara. Every effort has been made to verify the information in this table. The information included is not meant to be exhaustive but is intended to provide an overview of the subject matter.